BERLIN, Germany [November 11 – 13, 2025 ]
Anemocyte Srl, a leading provider of advanced manufacturing solutions and products for cell and gene therapies and nucleic acids-based medicines, is set to make a significant contribution to the 13th International mRNA Health Conference in Berlin and online, from November 11 to 13, 2025.
The company is proud to announce the debut of an innovative technology platform, designed to evolve the mRNA manufacturing of 5’capped mRNA.
Anemocyte will feature this groundbreaking platform in both a dedicated speech and a poster presentation, providing attendees with a comprehensive view of how such innovation addresses capping and manufacturing challeges in the rapidly evolving mRNA landscape.
The International mRNA Health Conference represents a leading global forum for the exchange of knowledge across the mRNA value chain — from discovery and development to manufacturing and delivery technologies.
The 2025 edition will gather experts from academia, biotech and pharmaceutical industries, CDMOs, and regulatory institutions to discuss current progress and future directions in the field.
Key topics will include:
- Innovations in mRNA therapeutics beyond vaccines, including protein replacement and immuno-oncology
- Manufacturing and analytical strategies for mRNA scale-up and quality control
- Emerging delivery systems and next-generation RNA constructs
- Global collaboration and regulatory considerations for mRNA-based medicines
Join our presentation and poster session:
- 11th november 2025 at 4:15 pm – Ballroom/lecture hall
- Poster number 28 – Poster hall
Participation in this event reflects Anemocyte’s continued commitment to contributing to the advancement of the mRNA ecosystem through innovation, technical excellence and partnership.
